



Press release

Bologna, 27 April 2012

IMA's AGM approves the 2011 financial statements

Dividend of 1 euro per share

Consolidated results at 31 December 2011 *

In millions of Euro	31.12.11	31.12.10	Δ% 11/10
Revenues	669.2	503.3	33.0
Gross operating profit (EBITDA) before non-recurring charges	91.6	62.3	47.0
Operating profit (EBIT)	66.5	43.2	53.9
Net profit for the year	29.1	17.4	67.2
Group net profit	28.0	17.0	64.7
Group order book	378.1	280.6	34.7
<i>Net financial position</i>	(157.5)	(113.5)	38.8

* The income statement and balance sheet figures include the contribution made by the Sympak Corazza Group, which has been consolidated since February 2011.

2011 dividend

The AGM approved a **dividend of 1 euro per share**, which is higher than last year (0.90 in 2011).

New plan approved for the purchase and sale of treasury shares

Remuneration report

Appointment of the new Board of Directors of IMA S.p.A.

The annual general meeting of the Shareholders of IMA S.p.A., world leader in the production of automatic machines, met today under the chairmanship of **Alberto Vacchi** and approved the financial statements at 31 December 2011.

The meeting resolved to distribute a **dividend of 1 euro per share**, higher than last year (0.90 euro), due for payment from 31 May 2012, going ex-coupon (no. 18) on 28 May 2012, allocating the balance to retained earnings.

Commenting on the Group results at 31 December 2011, **Alberto Vacchi, IMA's Chairman and CEO**, declared: *"This has been an excellent year, the best in the Group's 50-year history. The strong growth in revenues (33%), achieved thanks to a very positive trend in sales to our target sectors (pharmaceuticals and food) and the contribution of the Sympak Corazza Group, together with the increase in profits, confirm IMA's ability to keep on growing, creating innovation and value. IMA's ability to generate cash in 2011 has led to the decision to reward shareholders with a dividend of 1 euro, which is higher than last year's. For 2012 - continued Alberto Vacchi - we anticipate further growth in terms of both revenues and profitability, thanks to the excellent trend in the order book at the end of 2011 (+34.7% on the previous year) and to the orders received in the first three months of 2012, which are up by more than 9%. During 2012 - said the Chairman of IMA - our efforts will be aimed at strengthening our leadership in the pharmaceutical business and at consolidating the recent investments that we have made in the niche food packaging sector, boosting exports, which are a major engine of growth for our industry".*

New plan approved for the purchase and sale of treasury shares

The Shareholders' Meeting approved the renewal of the authorization to purchase and sale treasury shares to the extent permitted by law. The proposed purchase price is equal to the average stock price during the previous five days (+/-10%), while the proposed selling price will be at least the average purchase cost of the shares. As of today, IMA owns 55,000 treasury shares.

Remuneration report

The AGM also approved the Remuneration Policy under art. 123 ter D. Lgs. 58/98.

Appointment of the new Board of Directors of IMA S.p.A.

Lastly, the AGM appointed the **new Board of Directors of IMA S.p.A.** which will remain in office up to the AGM called to approve the financial statements at 31 December 2014; the Meeting also decided that the Board should consist of **12 members, including 3 independent directors.**

The AGM confirmed the 12 directors taken from the only list presented by the majority shareholder SO.FI.M.A. S.p.A.: **Alberto Vacchi, Marco Vacchi, Andrea Malagoli, Maria Carla Schiavina, Gianluca Vacchi, Luca Poggi, Italo Giorgio Minguzzi, Romano Volta, Enrico Ricotta** and the three independent directors - **Paolo Frugoni, Marco Galliani and Pierantonio Riello**.

The directors' CVs are available in the Investor Relations section of the Company's website (www.ima.it).

At the end of the Shareholders' Meeting, the IMA's Board of Directors met and confirmed **Alberto Vacchi** as Chairman and Chief Executive Officer of IMA S.p.A., conferring on him the relative powers. **Andrea Malagoli** was confirmed as the Pharma business Chief Executive Officer.

The Board of Directors assessed the status of the independent directors, **Paolo Frugoni, Marco Galliani and Pierantonio Riello**, pursuant to art. 148.3 of the Consolidated Finance Act and art. 3 of the Code of Conduct of Listed Companies.

The Board of Directors appointed **Marco Galliani, Pierantonio Riello and Maria Carla Schiavina** members of the Committee which includes the functions of the Nomination Committee, Remuneration Committee and Control and Risk Committee. Finally, the Board of Directors appointed **Paolo Frugoni** as Lead Independent Director.

The manager responsible for the preparation of the Company's accounting documents, Sergio Marzo, declares in accordance with article 154 bis paragraph 2 of the Consolidated Finance Act that the accounting information contained in this press release agrees with the books of account, the accounting entries and supporting documentation.

Established in 1961, IMA is world leader in the design and manufacture of automatic machines for the processing and packaging of pharmaceuticals, cosmetics, tea, coffee and foods. The Group has more than 3,400 employees, more than 1,500 of whom overseas, and can count on 22 production plants in Italy, Germany, the United Kingdom, the United States, India and China. IMA has an extensive sales network comprising 16 branches which provide sales and service in France, the United Kingdom, Germany, Austria, Spain, Portugal, Poland, Russia, the United States, China, Singapore, Thailand and Brazil, representative offices in Central and East European countries and over 50 agencies covering a total of more than 70 countries. IMA is also participating in one joint-venture in China for production and service. **IMA S.p.A. has been listed on the Milan Stock Exchange since 1995 and in 2001 joined the STAR segment.** The following manufacturing companies are part of the IMA Group: Co.ma.di.s. S.p.A., Corazza S.p.A., Gima S.p.A., IMA Industries S.r.l., IMA Kilian GmbH & Co. KG, IMA Life North America Inc., IMA Life (Beijing) Pharmaceutical Systems Co. Ltd., IMA North America Inc., IMA-PG India Pvt. Ltd., PharmaSiena Service S.r.l., Stephan Machinery GmbH, Swiftpack Automation Ltd., Zanchetta S.r.l.

For further information:

Andrea Baldani - Investor Relator - tel. +39 051 783111 - e-mail: baldania@ima.it

Maria Antonia Mantovani - Press Office - tel. +39 051 783283 - e-mail: antoniamantovani@ima.it

www.ima.it (Investor Relations section)